ERNA

Eterna Therapeutics Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website eternatx.com
Employees(FY) 9
ISIN US1140822099

Performance

-43.08%

-39.74%

-64.87%

-69.26%

-65.75%

YTD

-43.61%

Profile

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of ERNA 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be st...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ERNA

Stock Rank

Recent News & Updates

2024-11-13 19:30
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing(Globenewswire)
2024-10-29 20:30
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success(Globenewswire)
2024-10-17 20:06
Eterna, Factor announce license, collaboration agreement(Yahoo Finance)
2024-10-16 20:00
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases(Globenewswire)
2024-05-14 10:53
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-09 20:00
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i(Globenewswire)
2024-05-07 21:31
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board(Globenewswire)
2024-05-06 20:00
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i(Globenewswire)
2024-05-06 20:00
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus(Globenewswire)
2024-03-14 20:53
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023(Investorplace)
2024-02-19 19:30
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors(Globenewswire)
2024-01-03 03:15
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)(Globenewswire)
2023-12-20 22:18
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO(Yahoo Finance)
2023-12-20 03:15
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer(Globenewswire)
2023-12-14 05:56
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing(Globenewswire)
2023-11-01 23:48
Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors(Yahoo Finance)
2023-10-31 20:30
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors(Globenewswire)
2023-09-06 01:01
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies(Yahoo Finance)
2023-09-05 21:40
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics(Yahoo Finance)
2023-09-05 20:00
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics(Yahoo Finance)
2023-09-04 23:24
Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors(Yahoo Finance)
2023-09-04 20:30
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors(Yahoo Finance)
2023-07-18 02:24
Eterna Therapeutics Announces $8.7M Private Placement Transaction(Yahoo Finance)
2023-07-17 20:00
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing(Yahoo Finance)
2023-07-10 23:21
Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors(Yahoo Finance)
2023-07-10 20:30
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors(Yahoo Finance)
2023-05-23 23:18
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel(Yahoo Finance)
2023-05-23 20:30
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel(Yahoo Finance)
2023-05-16 20:30
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting(Yahoo Finance)
2023-05-03 20:30
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.